Sensitivity analysis for cumulative incidence of chronic health conditions in HCT recipients
| . | HCT survivor participants + deceased . | HCT survivor participants + deceased + HCT survivor nonparticipants . | ||||
|---|---|---|---|---|---|---|
| 2 years . | 5 years . | 10 years . | 2 years . | 5 years . | 10 years . | |
| Grades 1-5 | ||||||
| Overall | 0.32 (0.30-0.35) | 0.47 (0.45-0.50) | 0.59 (0.56-0.62) | 0.23 (0.21-0.25) | 0.34 (0.32-0.36) | 0.42 (0.39-0.44) |
| TBI yes | 0.35 (0.32-0.37) | 0.50 (0.47-0.53) | 0.62 (0.59-0.65) | 0.25 (0.23-0.27) | 0.36 (0.34-0.39) | 0.44 (0.41-0.47) |
| TBI no | 0.27 (0.22-0.31) | 0.40 (0.35-0.45) | 0.52 (0.47-0.58) | 0.18 (0.15-0.21) | 0.27 (0.24-0.31) | 0.35 (0.31-0.39) |
| No relapse | 0.37 (0.34-0.40) | 0.54 (0.51-0.57) | 0.67 (0.64-0.70) | 0.25 (0.23-0.27) | 0.36 (0.34-0.39) | 0.44 (0.42-0.47) |
| Autologous HCT | 0.28 (0.25-0.31) | 0.41 (0.37-0.45) | 0.54 (0.50-0.58) | 0.21 (0.19-0.24) | 0.31 (0.28-0.34) | 0.40 (0.37-0.43) |
| Allogeneic HCT | 0.37 (0.33-0.40) | 0.53 (0.50-0.57) | 0.64 (0.61-0.68) | 0.25 (0.22-0.27) | 0.36 (0.33-0.39) | 0.43 (0.40-0.46) |
| No chronic GVHD | 0.31 (0.26-0.36) | 0.44 (0.39-0.49) | 0.56 (0.51-0.62) | 0.20 (0.16-0.23) | 0.28 (0.24-0.31) | 0.35 (0.31-0.39) |
| With chronic GVHD | 0.42 (0.37-0.46) | 0.61 (0.57-0.66) | 0.72 (0.67-0.77) | 0.30 (0.26-0.33) | 0.43 (0.39-0.47) | 0.51 (0.47-0.55) |
| Grades 3-5 | ||||||
| Overall | 0.09 (0.08-0.11) | 0.24 (0.21-0.26) | 0.35 (0.32-0.39) | 0.07 (0.06-0.08) | 0.16 (0.14-0.17) | 0.22 (0.20-0.24) |
| TBI yes | 0.11 (0.09-0.12) | 0.25 (0.22-0.28) | 0.36 (0.33-0.40) | 0.08 (0.06-0.09) | 0.16 (0.14-0.18) | 0.23 (0.20-0.26) |
| TBI no | 0.07 (0.04-0.09) | 0.22 (0.17-0.26) | 0.33 (0.27-0.39) | 0.04 (0.03-0.06) | 0.14 (0.11-0.17) | 0.20 (0.16-0.24) |
| No relapse | 0.11 (0.09-0.13) | 0.28 (0.25-0.32) | 0.41 (0.37-0.45) | 0.07 (0.06-0.09) | 0.17 (0.15-0.19) | 0.23 (0.21-0.26) |
| Autologous HCT | 0.08 (0.06-0.09) | 0.20 (0.17-0.23) | 0.33 (0.28-0.37) | 0.06 (0.04-0.07) | 0.14 (0.12-0.17) | 0.22 (0.19-0.25) |
| Allogeneic HCT | 0.11 (0.09-0.14) | 0.28 (0.24-0.31) | 0.39 (0.34-0.43) | 0.08 (0.06-0.09) | 0.17 (0.14-0.19) | 0.23 (0.20-0.25) |
| No chronic GVHD | 0.08 (0.05-0.10) | 0.16 (0.12-0.20) | 0.26 (0.20-0.33) | 0.05 (0.03-0.07) | 0.09 (0.07-0.12) | 0.14 (0.11-0.18) |
| With chronic GVHD | 0.14 (0.11-0.18) | 0.37 (0.32-0.43) | 0.50 (0.43-0.57) | 0.10 (0.08-0.13) | 0.24 (0.20-0.28) | 0.31 (0.26-0.35) |
| . | HCT survivor participants + deceased . | HCT survivor participants + deceased + HCT survivor nonparticipants . | ||||
|---|---|---|---|---|---|---|
| 2 years . | 5 years . | 10 years . | 2 years . | 5 years . | 10 years . | |
| Grades 1-5 | ||||||
| Overall | 0.32 (0.30-0.35) | 0.47 (0.45-0.50) | 0.59 (0.56-0.62) | 0.23 (0.21-0.25) | 0.34 (0.32-0.36) | 0.42 (0.39-0.44) |
| TBI yes | 0.35 (0.32-0.37) | 0.50 (0.47-0.53) | 0.62 (0.59-0.65) | 0.25 (0.23-0.27) | 0.36 (0.34-0.39) | 0.44 (0.41-0.47) |
| TBI no | 0.27 (0.22-0.31) | 0.40 (0.35-0.45) | 0.52 (0.47-0.58) | 0.18 (0.15-0.21) | 0.27 (0.24-0.31) | 0.35 (0.31-0.39) |
| No relapse | 0.37 (0.34-0.40) | 0.54 (0.51-0.57) | 0.67 (0.64-0.70) | 0.25 (0.23-0.27) | 0.36 (0.34-0.39) | 0.44 (0.42-0.47) |
| Autologous HCT | 0.28 (0.25-0.31) | 0.41 (0.37-0.45) | 0.54 (0.50-0.58) | 0.21 (0.19-0.24) | 0.31 (0.28-0.34) | 0.40 (0.37-0.43) |
| Allogeneic HCT | 0.37 (0.33-0.40) | 0.53 (0.50-0.57) | 0.64 (0.61-0.68) | 0.25 (0.22-0.27) | 0.36 (0.33-0.39) | 0.43 (0.40-0.46) |
| No chronic GVHD | 0.31 (0.26-0.36) | 0.44 (0.39-0.49) | 0.56 (0.51-0.62) | 0.20 (0.16-0.23) | 0.28 (0.24-0.31) | 0.35 (0.31-0.39) |
| With chronic GVHD | 0.42 (0.37-0.46) | 0.61 (0.57-0.66) | 0.72 (0.67-0.77) | 0.30 (0.26-0.33) | 0.43 (0.39-0.47) | 0.51 (0.47-0.55) |
| Grades 3-5 | ||||||
| Overall | 0.09 (0.08-0.11) | 0.24 (0.21-0.26) | 0.35 (0.32-0.39) | 0.07 (0.06-0.08) | 0.16 (0.14-0.17) | 0.22 (0.20-0.24) |
| TBI yes | 0.11 (0.09-0.12) | 0.25 (0.22-0.28) | 0.36 (0.33-0.40) | 0.08 (0.06-0.09) | 0.16 (0.14-0.18) | 0.23 (0.20-0.26) |
| TBI no | 0.07 (0.04-0.09) | 0.22 (0.17-0.26) | 0.33 (0.27-0.39) | 0.04 (0.03-0.06) | 0.14 (0.11-0.17) | 0.20 (0.16-0.24) |
| No relapse | 0.11 (0.09-0.13) | 0.28 (0.25-0.32) | 0.41 (0.37-0.45) | 0.07 (0.06-0.09) | 0.17 (0.15-0.19) | 0.23 (0.21-0.26) |
| Autologous HCT | 0.08 (0.06-0.09) | 0.20 (0.17-0.23) | 0.33 (0.28-0.37) | 0.06 (0.04-0.07) | 0.14 (0.12-0.17) | 0.22 (0.19-0.25) |
| Allogeneic HCT | 0.11 (0.09-0.14) | 0.28 (0.24-0.31) | 0.39 (0.34-0.43) | 0.08 (0.06-0.09) | 0.17 (0.14-0.19) | 0.23 (0.20-0.25) |
| No chronic GVHD | 0.08 (0.05-0.10) | 0.16 (0.12-0.20) | 0.26 (0.20-0.33) | 0.05 (0.03-0.07) | 0.09 (0.07-0.12) | 0.14 (0.11-0.18) |
| With chronic GVHD | 0.14 (0.11-0.18) | 0.37 (0.32-0.43) | 0.50 (0.43-0.57) | 0.10 (0.08-0.13) | 0.24 (0.20-0.28) | 0.31 (0.26-0.35) |
Data are cumulative incidence (95% CI).